8-K: Vivos Therapeutics Extends Debt-to-Equity Swap Deadline

Vivos Therapeutics has extended the deadline for its $4.5 million debt-to-equity conversion agreement with Streeterville Capital to August 31, 2026.

Summary

• Vivos Therapeutics entered a letter agreement with Streeterville Capital to extend the deadline for a required $2.6 million qualifying financing.
• The original deadline of June 15, 2026, was extended to August 31, 2026.
• The agreement facilitates the conversion of up to $4.5 million of outstanding debt into perpetual, non-convertible preferred stock and common stock.
• The extension is intended to provide the company more time to conduct an organized equity raise and a planned rights offering.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative development; while the extension prevents an immediate default, it highlights the company's inability to meet original financing targets and ongoing liquidity pressure.

Positives

• Streeterville Capital reaffirmed its commitment to convert up to $4.5 million of debt into equity.
• The extension provides additional operational runway to complete the required $2.6 million financing.
• The restructuring supports the company's goal to strengthen stockholders' equity and maintain Nasdaq listing compliance.

Negatives

• The company failed to meet the original June 15, 2026, deadline for the qualifying financing.
• Failure to meet the new August 31, 2026, deadline could jeopardize the debt-to-equity conversion agreement.
• The company remains dependent on external financing to maintain its balance sheet and listing status.

Risks

• Inability to raise the required $2.6 million in new equity by August 31, 2026.
• Risk of losing the debt-to-equity conversion benefit if the financing conditions are not met.
• Potential for delisting from Nasdaq if stockholders' equity requirements are not satisfied.
• Reliance on the cooperation of a single creditor (Streeterville Capital) for debt restructuring.

Future Outlook

The company aims to complete a $2.6 million equity raise and a rights offering by August 31, 2026, to strengthen its balance sheet and maintain Nasdaq listing compliance.

Management Comments

• R. Kirk Huntsman expressed gratitude for Streeterville's cooperation in extending the deadline.
• Management believes the company has successfully pivoted to its new strategic business model and is performing well.

Industry Context

StockSavvy.ai notes that small-cap medical device companies frequently utilize debt-to-equity swaps to manage liquidity and avoid dilution or insolvency, though such reliance on specific creditors highlights ongoing capital constraints in the sector.

Comparison to Industry Standards

• The use of 'at-the-market' or 'rights offering' structures is common for micro-cap healthcare firms facing Nasdaq compliance issues.
• The reliance on Streeterville Capital is consistent with high-cost, non-dilutive financing strategies often seen in distressed small-cap biotech/medtech firms.

Stakeholder Impact

• Shareholders face potential dilution from the equity raise and debt-to-equity conversion.
• Creditors (Streeterville) gain equity stakes in exchange for debt relief.

Next Steps

• Execute the $2.6 million equity financing by August 31, 2026.
• Launch the planned rights offering.
• Complete the debt-to-equity conversion with Streeterville Capital.

Key Dates

Recommendation

The company is in a precarious financial position requiring immediate capital to maintain listing status. Investors should wait for evidence of successful capital raising before considering a position.

Keywords

Vivos Therapeutics, VVOS, Debt-to-Equity, Streeterville Capital, Sleep Apnea, Nasdaq, Financing